Its results lean toward supporting the maintenance/introduction of SGLT2 inhibitors shortly after an episode of AKI, serving as a prelude to ongoing controlled studies (NCT05360615) that will ultimately provide a definitive answer to the research question presented by Murphy et al.7 This evidence concerns the gene SLC5A2 and acute kidney injury.